As Amgen's Q2 earnings call revealed robust financial performance with رفعd guidance, the stock should experience a moderate positive impact in the short term (1-2 weeks). However, some concerns around the novelty and safety of some pipeline drugs may cap these gains. The strong financial performance, marked by double-digit revenue and EPS growth, along with increased guidance, is a strong indicator of the company's fundamentally sound position. Notably, theAlmanepth speculated about thecontended legal battle with Roche over EPO implies a robust legal strategy, Instilling some certainty around intellectual property rights.  
[1]